The gut microbiota, a diverse community of microorganisms residing in the gastrointestinal tract, plays a vital role in maintaining overall health through digestion, nutrient production, and immune modulation. Factors such as diet, lifestyle, and medication use significantly influence its composition. Concurrently, the blood-brain barrier (BBB) serves as a crucial protective barrier, regulating the passage of substances between the bloodstream and the brain. Disruption of the BBB is linked to various neurological disorders and cognitive decline. Neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's, can be exacerbated by compromised BBB integrity, allowing harmful substances to penetrate the brain and accelerate neuronal degeneration. This review examines the complicated relationship between gut microbiota and BBB integrity, focusing on their collective impact on neurodegenerative diseases. Despite advancements in understanding these systems independently, there remains a critical gap in comprehending their interconnected roles in neurodegeneration. Addressing this gap is paramount for developing innovative therapeutic strategies. Specifically, this review suggests that modulating the gut microbiota offers a promising and actionable approach to preserve BBB integrity, thereby presenting a novel avenue for mitigating neurodegeneration and improving the prognosis and quality of life for affected individuals.
Gastrointestinal (GI) malignancies are notable for their high global health burden, bringing the toll of more than two million deaths every year and the evolution of the treatment paradigm. In this review, we discuss mRNA-based vaccines as an emerging treatment modality for both of these cancers and their transformative potential. We discuss the rapid development of mRNA as a platform technology, focusing on its unique versatility for customizable neoantigen targeting, its promising safety history, and its anticipated role in the field of immuno-oncology for the future. The review describes mRNA vaccines currently in development and discusses the overall landscape of clinical trials in GI cancers. We dissect significant learning in patient stratification, choice of trial design, and efficacy readouts by discussing completed and ongoing studies, including the positive results observed in pancreatic ductal adenocarcinoma. Although the potential is excellent, hurdles are also high. We discuss the immunological, technical, and logistical challenges, such as the immunosuppressive TME and the optimal delivery systems that currently prevent its wide clinical application. This review not only demonstrates the potential of mRNA vaccines to transform the treatment landscape in the field of GI cancers but also paves the way for future investigations, highlighting the importance of precision medicine in circumventing the challenges encountered to date and potentially changing the treatment platform altogether.
The leading factor contributing to patient mortality is the local invasion and metastasis of tumors, which are influenced by the malignant progression of tumor cells. The epithelial-mesenchymal transition (EMT) is key to understanding malignancy development. EMT is a critical regulatory mechanism for differentiating cell populations initially observed during the neural crest and embryonic gastrulation formation. This process is closely associated with tumor metastasis in cancer and is also related to the maintenance of cancer stem cells. Flavonoids, known for their antioxidant properties, have been widely studied for their anticancer potential to protect plants from harmful environmental conditions. They have attracted considerable attention and have been the focus of numerous experimental and epidemiological studies to evaluate their potential in cancer treatment. In vitro and in vivo research has demonstrated that flavonoids can significantly impact cancer-related EMT. They may inhibit the EMT process by reducing the levels of Twist1, N-cadherin, ZEB1, integrins, SNAI1/2, CD44, MMPs, and vimentin while increasing E-cadherin levels and targeting the PI3K/AKT, NF-κB p65, and JAK2/STAT3 signaling pathways. In order to suppress the transcription of the E-cadherin promoter, several Zn-finger transcription factors, such as SNAI2, ZEB1, and ZEB2, and basic helix-loop-helix (bHLH) factors, such as Twist, may directly bind to its E-boxes. Overall, clinical cancer research should integrate the anticancer properties of flavonoids, which address all phases of carcinogenesis, including EMT, to improve the prospects for targeted cancer therapies in patients suffering from aggressive forms of tumors.
Urinary tract infections (UTIs) are becoming more common, requiring extensive protection from antimicrobials. The global expansion of multi-drug resistance uropathogens in the past decade emphasizes the necessity of newer antibiotic treatments and prevention strategies for UTIs. Medicinal plants have wide therapeutic applications in both the prevention and management of many ailments. Bacopa monnieri is a medicinal plant that is found in the warmer and wetlands regions of the world. It has been used in Ayurvedic systems for centuries. The present study aimed to investigate the antibacterial potential of the extract of B. monnieri leaves and its bioactive molecules against UTIs that are caused by Klebsiella pneumoniae and Proteus mirabilis. This in vitro experimental study was conducted by an agar well diffusion method to evaluate the antimicrobial effect of 80% methanol, 96% ethanol, and aqueous extracts of B. monnieri leaves on uropathogens. Then, further screening of their phytochemicals was carried out using standard methods. To validate the bioactive molecules and the microbe interactions, AutoDock Vina software was used for molecular docking with the Klebsiella pneumoniae fosfomycin resistance protein (5WEW) and the Zn-dependent receptor-binding domain of Proteus mirabilis MR/P fimbrial adhesin MrpH (6Y4F). Toxicity prediction and drug likeness were predicted using ProTox-II and Molinspiration, respectively. A molecular dynamics (MD) simulation was carried out to study the protein ligand complexes. The methanolic leaves extract of B. monnieri revealed a 22.3 mm ± 0.6 mm to 25.0 mm ± 0.5 mm inhibition zone, while ethanolic extract seemed to produce 19.3 mm ± 0.8 mm to 23.0 mm ± 0.4 mm inhibition zones against K. pneumoniae with the use of increasing concentrations. In the case of P. mirabilis activity, the methanolic extracts showed a 21.0 mm ± 0.8 mm to 24.0 mm ± 0.6 mm zone of inhibition and the ethanol extract produced a 17.0 mm ± 0.9 mm to 23.0 mm ± 0.7 mm inhibition zone with increasing concentrations. Carbohydrates, flavonoids, saponin, phenolic, and terpenoid were common phytoconstituents identified in B. monnieri extracts. Oroxindin showed the best interactions with the binding energies with 5WEW and 6Y4F, -7.5 kcal/mol and -7.4 kcal/mol, respectively. Oroxindin, a bioactive molecule, followed Lipinski's rule of five and exhibited stability in the MD simulation. The overall results suggest that Oroxindin from B. monnieri can be a potent inhibitor for the effective killing of K. pneumoniae and P. mirabilis. Additionally, its safety has been established, indicating its potential for future drug discovery and development in the treatment for UTIs.